Syncope
Introduction
Overview
Syncope, commonly known as fainting, is defined as a transient loss of consciousness caused by a temporary reduction in global cerebral blood flow. It is characterized by a sudden onset, short duration, and spontaneous recovery. [1] Syncope is a common condition in the general population, accounting for approximately 1% of all visits to European emergency departments. [2] Its incidence rates range from 2.6 to 19.5 per 1000 person-years and occur more frequently in women than men, with the highest incidence observed in women over 80 years old. [3]
Syncope can be broadly classified into neurally-mediated reflex syncope (which includes vasovagal syncope), syncope due to orthostatic hypotension, and cardiac syncope. Vasovagal syncope is the most frequent type. [4] While the overall mortality rate associated with syncope is relatively low (0.28%), the risk is highest for cardiac syncope. [5]
Biological Basis and Genetics
The transient loss of consciousness in syncope fundamentally arises from a temporary reduction in blood flow to the brain. Research indicates that syncope has a distinct genetic architecture involving neural regulatory processes and a complex relationship with heart rate and blood pressure regulation. [6]
Family aggregation studies and twin studies suggest a complex inheritance pattern for vasovagal syncope. [7] Recent large-scale genome-wide association studies (GWAS) have begun to uncover specific genetic variants associated with syncope. For example, one meta-analysis identified 18 independent syncope variants, with 17 being novel. One such variant, p.Ser140Thr in PTPRN2, was found to affect syncope when maternally inherited. [6] These studies suggest that syncope-associated variants are preferentially located in neural-specific regulatory regions. [6] Another GWAS identified a novel genome-wide significant locus at chromosome 2q32.1, with rs12465214 identified as a lead SNP. [8]
Genetic correlations have been observed with various physiological traits and conditions. These include heart rate and blood pressure regulation, as well as a shared genetic background with coronary artery disease, angina, hypertension, body mass index, and atrial fibrillation. [6] Furthermore, genetic overlap has been noted with psychiatric phenotypes such as depression and attention deficit hyperactivity. [8] Cell-type specific analyses have revealed a significant enrichment of syncope-associated SNPs in adrenal and pancreas regulatory elements, suggesting an involvement of the endocrine system in syncope pathogenesis. [8]
Clinical and Social Importance
Syncope is a clinically challenging condition due to its diverse underlying causes, which can range from benign factors to life-threatening diseases. Predisposing factors include genetic cardiac arrhythmias such as long QT and short QT syndromes, Brugada syndrome, and catecholaminergic polymorphic ventricular tachycardia. [9] In some instances, syncope may be the only presenting symptom of these serious underlying cardiac conditions. [10] The occurrence of syncope within 24 hours preceding death has been observed in a significant percentage of young victims of sudden death. [11]
Despite the high utilization of diagnostic tests, the diagnostic yield for syncope remains low (30–48%), underscoring the need for improved understanding of its pathophysiology and more effective diagnostic strategies. [1] From a societal perspective, syncope contributes to a substantial number of emergency department visits and can significantly impact an individual's quality of life. Women, for example, experience a nearly doubled hazard rate for syncope compared to men. [8] The observed genetic overlap with overall health and cardiovascular health emphasizes the importance of a thorough assessment for individuals presenting with syncope. [6]
Methodological and Statistical Considerations
Despite the substantial sample sizes employed in recent genome-wide association studies (GWAS) for syncope, certain methodological and statistical limitations warrant consideration. Earlier genetic investigations into syncope, particularly vasovagal syncope, were often hampered by small participant cohorts (n = 50–150), leading to insufficient statistical power and difficulties in replicating initial findings . This intergenic variant, situated approximately 250 kb downstream of the ZNF804A gene, is thought to exert its influence by affecting the expression levels of ZNF804A. [8] ZNF804A is highly expressed in brain tissue, cerebral arteries, and endocrine glands, but shows negligible expression in the heart, suggesting that its role in syncope is likely mediated through neurological or vascular mechanisms rather than direct cardiac effects. The genetic predisposition to syncope also shows overlap with psychiatric conditions such as attention deficit hyperactivity and depression, indicating potential shared biological pathways involving neural regulation. [8]
Other variants, such as rs12614706, are found near the CACYBPP2 and MIR548AE1 genes, while rs1431318 is associated with ANKFN1. CACYBPP2 is a pseudogene, which typically does not code for functional proteins but can play regulatory roles, for instance, by influencing the stability or expression of other RNAs or genes. MIR548AE1 encodes a microRNA, a small non-coding RNA molecule that finely tunes gene expression by binding to messenger RNAs, thereby impacting various cellular processes including neural development and function. ANKFN1 (Ankyrin repeat and fibronectin type III domain containing 1) encodes a protein with domains commonly involved in protein-protein interactions and cell adhesion, which are critical for maintaining cellular structure and signaling pathways, particularly in the nervous system. The involvement of such genes suggests that subtle alterations in gene regulation and protein interactions within neural circuits or vascular control systems may contribute to syncope susceptibility. [6]
Further variants, including rs4522506 linked to CTBP2P3 and HMGN1P31, and rs74667074 associated with LARP7P4 and GM2AP1, underscore the diverse genetic landscape influencing syncope. CTBP2P3 and HMGN1P31 are pseudogenes related to CTBP2 and HMGN1, respectively, which are involved in chromatin remodeling and gene transcription regulation. Changes in chromatin structure can alter gene accessibility and expression, profoundly affecting the development and function of neural and autonomic systems. Similarly, LARP7P4 is a pseudogene related to LARP7, a gene crucial for RNA processing and stability, while GM2AP1 is a pseudogene linked to GM2AP, a gene involved in lipid metabolism within lysosomes. These pseudogenes, potentially acting as regulatory elements, may contribute to syncope risk by modulating the expression of their functional counterparts or other genes involved in cellular maintenance, neuronal signaling, or autonomic control. [6] Understanding these genetic influences provides insights into the underlying neural and autonomic dysregulation characteristic of syncope.
Definition and Core Characteristics
Syncope is precisely defined as a transient loss of consciousness caused by short-term global cerebral hypoperfusion. [1] This condition is characterized by its sudden onset, brief duration, and spontaneous, complete recovery, distinguishing it from other causes of transient loss of consciousness. [1] The underlying conceptual framework centers on the temporary reduction of blood flow to the entire brain, which is critical for maintaining consciousness and normal neurological function. Understanding these core characteristics is fundamental for accurate diagnosis and differentiation from conditions like seizures or coma.
Classification and Etiological Subtypes
Syncope is broadly classified into three main categories based on its etiology: neurally-mediated reflex syncope (also known as neurocardiogenic syncope), syncope due to orthostatic hypotension, and cardiac syncope. [8] Within neurally-mediated reflex syncope, vasovagal syncope (VVS) is identified as the most prevalent subtype, often triggered by emotional stress or prolonged standing. [8] The clinical significance of these classifications is paramount, as cardiac syncope, often associated with underlying cardiac diseases such as genetic arrhythmias including long QT, short QT, Brugada syndrome, and catecholaminergic polymorphic ventricular tachycardia, carries the highest risk of mortality. [5] Predisposing factors for syncope are wide-ranging, encompassing life-threatening diseases, side effects from pharmacological agents, and benign causes. [12]
Standardized Terminology and Diagnostic Criteria
In clinical and research contexts, syncope is often discussed using standardized terminology such as "syncope and collapse," reflecting its presentation. [8] Operational definitions for syncope in large-scale studies frequently rely on International Classification of Disease (ICD) codes, with ICD-9 code 780.2, ICD-10 code R55, and ICD-8 code 782.5 commonly employed. [8] The use of ICD-10 code R55 for syncope and collapse has been validated with a positive predictive value of 95%, making it a reliable diagnostic criterion for population-based research. [13] However, a limitation of using general ICD codes like R55 is their inability to distinguish between the various subtypes of syncope, which can impact the granularity of research findings. [8] Despite the array of diagnostic tests available, the overall diagnostic yield for syncope remains relatively low, typically ranging from 30% to 48%, underscoring the diagnostic challenge. [8] Furthermore, related concepts such as drug-induced prolongation of the electrocardiographic QT interval are recognized as increasing the risk of syncope. [14]
Clinical Presentation and Phenotypic Variability
Syncope is clinically defined as a transient loss of consciousness resulting from short-term global cerebral hypoperfusion, characterized by sudden onset, brief duration, and spontaneous recovery . Research indicates a distinct genetic architecture underlying this common condition, often implicating neural and autonomic processes, and a significant overlap with cardiovascular health. [6]
Genetic Architecture and Inherited Risk
Genetic factors play a substantial role in susceptibility to syncope, with family aggregation studies suggesting complex inheritance patterns for conditions like vasovagal syncope, and twin studies demonstrating higher concordance rates in monozygotic twins compared to dizygotic pairs. [8] Genome-wide association studies (GWAS) have identified specific loci and single nucleotide polymorphisms (SNPs) associated with syncope risk, such as a novel locus at chromosome 2q32.1, where the lead SNP rs12465214 carries an increased risk for the C allele. [8] More broadly, meta-analyses have revealed 18 independent syncope variants, including a p.Ser140Thr variant in PTPRN2 that influences syncope when maternally inherited, highlighting potential imprinting effects. [6]
Beyond specific variants, syncope exhibits a polygenic risk and shares a genetic background with several other health traits. Studies indicate a significant genetic correlation with overall self-reported health, inversely correlating with hand grip strength, a general health proxy. [8] Furthermore, a strong genetic overlap exists with coronary artery disease, as well as related conditions such as angina, hypertension, body mass index, and atrial fibrillation, emphasizing the broad influence of genetic predisposition on cardiovascular health in relation to syncope. [8] Genetic correlations have also been observed with psychiatric phenotypes, including attention deficit hyperactivity and depression, suggesting a shared etiological basis for some aspects of syncope and mental health conditions. [8]
Neural and Autonomic Dysregulation
The pathophysiology of syncope is intrinsically linked to dysregulation within the neural and autonomic nervous systems, which control vital functions such as heart rate and blood pressure. [6] Genetic variants associated with syncope are preferentially located in neural-specific regulatory regions, indicating their role in modulating nerve function critical for maintaining cerebral perfusion. [6] These variants often affect heart rate and/or blood pressure regulation, with diverse effects that can contribute to the transient global cerebral hypoperfusion characteristic of syncope. [6]
Further insights into the mechanisms come from partitioned heritability analyses, which show a significant enrichment of regulatory elements in adrenal and pancreas cell types. [8] This finding suggests an involvement of the endocrine system in syncope pathogenesis, as these organs are crucial for stress response and metabolic regulation, both of which can impact cardiovascular stability and autonomic tone. [8] For example, some variants have been specifically associated with vasovagal reactions, a common type of neurally-mediated syncope, underscoring the direct impact on autonomic reflexes. [6]
Interacting Factors and Comorbidities
Syncope often occurs in the context of other health conditions and can be influenced by demographic and environmental factors. Individuals with underlying cardiac diseases, particularly genetic cardiac arrhythmias such as long QT syndrome, short QT syndrome, Brugada syndrome, and catecholaminergic polymorph ventricular tachycardia, frequently experience syncope. [8] In some severe cases, syncope may be the sole presenting symptom of these life-threatening cardiac conditions, necessitating careful evaluation. [8] Beyond cardiac issues, general health status, medication effects, and even psychiatric conditions can contribute to syncope risk.
The risk of syncope is further modulated by age and sex, with women experiencing an almost doubled hazard rate compared to men. [8] The highest incidence rates are observed in women over 80 years of age, though the median age of onset in some cohorts can be much younger, around 18 years. [8] Additionally, certain medications, such as psychotropic drugs, can lead to QTc-interval abnormalities that predispose individuals to syncope. [8] While specific environmental exposures or lifestyle factors are not extensively detailed, the observed genetic correlations with broad health indicators like overall health rating and cardiovascular disease suggest that a combination of genetic predisposition and environmental influences on cardiovascular well-being likely contributes to syncope risk. [8]
Defining Syncope: A Transient Loss of Cerebral Perfusion
Syncope is characterized as a transient loss of consciousness resulting from a temporary, global reduction in blood flow to the brain, known as cerebral hypoperfusion. This condition manifests with a sudden onset, short duration, and spontaneous, complete recovery. [1] It is a common clinical event, often classified into neurally-mediated reflex syncope (including vasovagal syncope, the most frequent type), syncope due to orthostatic hypotension, and cardiac syncope. [4] Incidence rates vary, but syncope is observed more frequently in women, particularly those over 80 years of age . [3], [4]
The fundamental pathophysiological process underlying syncope involves a disruption in the homeostatic mechanisms that maintain adequate cerebral blood flow. This disruption leads to a critical decrease in oxygen and nutrient supply to brain tissue, triggering the transient loss of consciousness. While typically brief and self-resolving, syncope can be a symptom of more severe underlying conditions, underscoring the importance of understanding its biological underpinnings. [5] The diverse classifications suggest a range of mechanisms, all converging on the common pathway of insufficient cerebral perfusion.
Genetic Foundations and Regulatory Networks
Recent genome-wide association studies (GWAS) have revealed a distinct genetic architecture for syncope, implicating specific loci and regulatory elements. One significant locus identified is on chromosome 2q32.1, with the lead single nucleotide polymorphism (SNP) rs12465214 showing a strong association with syncope risk. [8] This finding has been replicated in independent cohorts, reinforcing its relevance to syncope susceptibility. [8] Further research has uncovered 18 independent syncope variants, 17 of which were novel, highlighting the complex polygenic nature of the condition. [6]
Among these variants, a specific p.Ser140Thr mutation in the PTPRN2 gene was found to influence syncope risk exclusively when maternally inherited, suggesting potential imprinting effects or other complex genetic mechanisms. [6] Annotation of syncope-associated variants indicates a preferential location within neural-specific regulatory regions, pointing to the importance of gene expression control in the nervous system. [6] Additionally, partitioned heritability analyses have shown a significant enrichment of regulatory elements, partly driven by the discovered risk locus, which suggests an involvement of the endocrine system in syncope pathogenesis. [8] Family aggregation and twin studies further support a complex genetic inheritance pattern for vasovagal syncope, with higher concordance rates in monozygotic twins. [7]
Autonomic and Neuro-Cardiovascular Control
Syncope is intimately linked to the regulation of the autonomic nervous system, which governs involuntary bodily functions like heart rate and blood pressure. Genetic variants associated with syncope have been found to influence these crucial physiological parameters, with variable effects on their regulation. [6] Molecular and cellular pathways involving specific receptors and signaling proteins play a critical role in mediating these autonomic responses. For instance, polymorphisms in the beta1-adrenergic receptor gene (ADRB1) and the alpha1a-adrenergic receptor gene (ADRA1A) have been associated with susceptibility to vasovagal syncope, indicating altered adrenergic signaling. [15]
Further, variations in the gene encoding the alpha subunit of the human Gs protein (GNAS), a key component of G protein-coupled receptor signaling pathways, have been linked to a predisposition for vasovagal syncope. [16] The adenosine A2A receptor gene (ADORA2A) and polymorphisms within the endothelin system have also been implicated in tilt-test induced vasovagal syncope, highlighting the diverse molecular pathways involved in neuro-cardiovascular control . [17], [18] These findings collectively underscore how genetic variations can modulate the intricate neural and autonomic processes that maintain cardiovascular stability, and how their dysregulation can lead to episodes of syncope.
Systemic Interconnections and Disease Pathophysiology
Syncope often presents as a symptom within a broader context of systemic health, particularly involving the cardiovascular and endocrine systems. Studies have revealed a shared genetic background between syncope and indicators of poorer cardiovascular health, such as coronary artery disease, angina, hypertension, and atrial fibrillation . [6], [8] Mendelian randomization analysis has further supported a causal relationship, suggesting that coronary artery disease can contribute to syncope risk. [6] This indicates that the mechanisms leading to syncope are not isolated but are deeply interconnected with overall cardiovascular well-being.
Syncope is also a frequent occurrence in individuals with underlying genetic cardiac arrhythmias, including long and short QT syndromes, Brugada syndrome, and catecholaminergic polymorphic ventricular tachycardia . [5], [9] In some severe cases, syncope may be the sole presenting symptom of these life-threatening cardiac conditions, emphasizing the critical link between cardiac electrical stability and cerebral perfusion. [5] Beyond the cardiovascular system, a significant enrichment of syncope-associated SNPs in regulatory elements of adrenal and pancreas tissues points to an involvement of the endocrine system in its pathogenesis. [8] Furthermore, genetic overlaps have been observed between syncope and certain psychiatric phenotypes, such as attention deficit hyperactivity and depression, suggesting complex systemic interactions that influence susceptibility to this condition. [8]
Neuroautonomic Signaling and Receptor Pathways
Syncope, particularly neurally-mediated reflex syncope, involves intricate signaling pathways that govern autonomic function and cardiovascular responses. Genetic variants have been identified that modulate the sensitivity and function of key receptors involved in blood pressure and heart rate regulation. For instance, polymorphisms in adrenergic receptors, such as the Arg389Gly variant in the beta1-adrenergic receptor (ADRB1) and the Arg347Cys variant in the alpha1a-adrenergic receptor (ADRA1A), are associated with individual susceptibility to syncope and fainting episodes. [15] These receptors, when activated, initiate intracellular signaling cascades, often through G protein-coupled mechanisms, that ultimately influence vascular tone and myocardial contractility. A mutation (T/C, Ile 131) in the gene encoding the alpha subunit of the human Gs protein has also been linked to predisposition for vasovagal syncope, highlighting the critical role of G protein signaling in this neuroautonomic dysregulation. [16] Furthermore, adenosine A2A receptor gene polymorphism is associated with head-up tilt-induced syncope, suggesting a role for purinergic signaling in the complex reflex pathways leading to transient cerebral hypoperfusion. [17]
Genetic Regulation and Transcriptional Control
The genetic architecture of syncope implicates specific regulatory mechanisms at the gene level, influencing the expression and function of proteins crucial for neural and cardiovascular stability. Genome-wide association studies (GWAS) have identified novel genetic loci, such as one on chromosome 2q32.1, with a lead SNP rs12465214, significantly associated with syncope. [8] This locus, along with other syncope-associated variants, is preferentially located in neural-specific regulatory regions, suggesting that altered gene regulation within the nervous system contributes to syncope pathophysiology. [6] Beyond neural regulation, partitioned heritability analyses indicate a significant enrichment of regulatory elements in tissues like the adrenal glands and pancreas, implying a broader endocrine involvement in syncope pathogenesis. [8] Specific gene variants, such as p.Ser140Thr in PTPRN2, have been shown to affect syncope risk, particularly when maternally inherited, underscoring the complex genetic and potentially epigenetic regulatory layers that modulate susceptibility. [6]
Cardiovascular and Systemic Integration
Syncope manifests as a transient loss of consciousness due to global cerebral hypoperfusion, often stemming from complex interactions between the cardiovascular and nervous systems. Genetic variants associated with syncope exhibit a complex relationship with fundamental physiological parameters like heart rate and blood pressure regulation, indicating that dysregulation in these integrated systems is central to the condition. [6] The endothelin system, a potent regulator of vascular tone, also shows polymorphisms in tilt test-induced vasovagal syncope, highlighting its contribution to the neurovascular instability characteristic of reflex syncope. [18] Furthermore, syncope is a recognized symptom in various underlying cardiac diseases, including genetic arrhythmias such as long QT syndrome, short QT syndrome, Brugada syndrome, and catecholaminergic polymorphic ventricular tachycardia, where it can be the sole presenting symptom. [8] This broad association underscores the critical systems-level integration where cardiac electrical stability, vascular regulation, and autonomic control must operate in concert to prevent cerebral hypoperfusion.
Pathway Dysregulation and Disease Mechanisms
The pathophysiology of syncope involves the dysregulation of multiple interconnected pathways, leading to a breakdown in compensatory mechanisms that normally maintain cerebral blood flow. A significant genetic overlap has been observed between syncope and various psychiatric phenotypes, including anxiety, attention deficit hyperactivity, and depression, suggesting shared underlying biological pathways or a common vulnerability to dysregulation. [8] Mendelian randomization analysis has supported a causal effect of coronary artery disease on syncope, indicating that broader cardiovascular health issues can directly contribute to syncope risk by affecting systemic blood flow and regulatory capacity. [6] The identification of genetic variants within neural-specific regulatory regions points to primary dysfunctions in the central and autonomic nervous system's ability to appropriately respond to physiological stressors, leading to inadequate heart rate and blood pressure adjustments. [6] Understanding these points of pathway dysregulation and their systemic consequences offers potential avenues for improved risk stratification and the development of targeted therapeutic strategies.
Epidemiological Patterns and Demographic Correlates
Syncope is a common condition within the general population, frequently leading to emergency department visits, accounting for approximately 1% of all such visits in Europe. [2] Epidemiological studies have reported incidence rates ranging from 2.6 to 19.5 per 1000 person-years. [8] A study of 549 Dutch individuals aged 35-60 years provided insights into the lifetime cumulative incidence of the condition. [3] The occurrence of syncope demonstrates a clear demographic pattern, being more frequent in women than men, with the highest incidence rates observed in women over 80 years of age. [8]
Beyond incidence, population-level analyses have also addressed the mortality associated with syncope. In the United States, the overall mortality rate reported between 2000 and 2005 was 0.28%, with cardiac syncope carrying the highest risk of mortality. [5] Genetic correlation studies have revealed significant overlaps between syncope and various health traits, including self-reported overall health status, which showed a strong correlation, and a negative correlation with hand grip strength. [8] Furthermore, syncope exhibits genetic correlations with cardiovascular conditions such as coronary artery disease, angina, hypertension, body mass index, and atrial fibrillation, as well as psychiatric phenotypes like anxiety, depression, and attention deficit hyperactivity. [8]
Large-Scale Genetic Cohort Studies and Biobank Applications
Large-scale cohort studies, particularly those leveraging biobanks, have been instrumental in uncovering the genetic underpinnings of syncope. The UK Biobank, with its extensive phenotypic and genotypic data from over 500,000 participants, has served as a critical resource for such investigations. [8] One genome-wide association study (GWAS) conducted on 408,961 ethnically matched individuals from the UK Biobank (9,163 cases and 399,798 controls) identified a novel genome-wide significant locus at chromosome 2q32.1, with the lead SNP rs12465214 showing an odds ratio of 1.13 for the risk allele C. [8] This finding was subsequently replicated in an independent cohort from the Danish National Biobank (iPSYCH study), which included 54,656 individuals with a median follow-up of 24.86 years, confirming the association of rs12465214 with incident syncope. [8]
Further expanding on these efforts, a large-scale genome-wide association meta-analysis included 56,071 syncope cases and 890,790 controls from diverse populations across deCODE genetics (Iceland), UK Biobank, and the Copenhagen Hospital Biobank/Danish Blood Donor Study. [6] This comprehensive study identified 18 independent genetic variants associated with syncope, 17 of which were novel, and these findings were further validated in replication cohorts from Intermountain (Utah, USA) and FinnGen (Finland). [6] Notably, one variant, p.Ser140Thr in PTPRN2, was found to affect syncope risk specifically when maternally inherited, and several other variants were linked to heart rate and blood pressure regulation. [6] The variants identified in these studies were preferentially located in neural-specific regulatory regions, suggesting a role for neural and autonomic processes in syncope pathophysiology. [6]
Cross-Population Genetic Insights and Methodological Approaches
Cross-population comparisons in genetic studies have provided valuable insights into the generalizability of syncope risk loci. The initial discovery of the rs12465214 locus in individuals of British ancestry from the UK Biobank was successfully replicated in a Danish cohort, demonstrating the transferability of this genetic association across European populations. [8] The broader meta-analysis encompassed populations from Iceland, the United Kingdom, Denmark, the United States, and Finland, confirming the robustness of the identified genetic variants across diverse ethnic backgrounds. [6] These studies highlight the importance of large, multi-ethnic cohorts in validating genetic findings and understanding population-specific effects, though specific ancestry differences in prevalence or genetic architecture were not detailed.
Methodologically, these population studies employed rigorous designs to ensure reliable findings. Syncope cases were typically defined using International Classification of Disease (ICD) codes, such as ICD-9 code 780.2 and ICD-10 code R55 in the UK Biobank, and ICD-8 code 782.5 or ICD-10 code R55 in the Danish cohorts. [8] Statistical analyses involved logistic mixed models and hazard ratio calculations, adjusted for covariates like kinship coefficients, principal components, sex, and age. [8] Extensive quality control measures were applied to genetic data, including tests for batch effects, deviations from Hardy–Weinberg equilibrium, sex effects, and sample-based checks for sex mismatch and extreme heterozygosity, ensuring data integrity and representativeness. [8] This robust methodology addresses limitations of earlier studies, which often suffered from small sample sizes and lacked successful replication. [8]
Key Variants
| RS ID | Gene | Related Traits |
|---|---|---|
| rs12465214 rs12614706 |
CACYBPP2 - MIR548AE1 | syncope |
| rs1431318 | ANKFN1 | cannabis dependence syncope |
| rs4522506 | CTBP2P3 - HMGN1P31 | syncope |
| rs74667074 | LARP7P4 - GM2AP1 | syncope |
Frequently Asked Questions About Syncope
These questions address the most important and specific aspects of syncope based on current genetic research.
1. My parent faints a lot; will I also faint easily?
Yes, family studies suggest a complex inheritance pattern for syncope, especially vasovagal syncope. If a parent experiences it, you might have a higher genetic predisposition. This is because certain genetic variants, like those affecting neural regulatory processes, can be passed down and influence your susceptibility. However, it's a complex trait, meaning many factors beyond just genetics play a role.
2. Why do my female friends seem to faint more often?
Research shows syncope occurs more frequently in women than men, with women experiencing a nearly doubled hazard rate. While not fully understood, this suggests biological differences, potentially influenced by sex-linked genetic factors or hormonal regulation. The highest incidence is observed in women over 80 years old, highlighting age and gender as important considerations.
3. Can exercising too hard make me more likely to faint?
Syncope is fundamentally about your body's ability to regulate blood flow to the brain, which involves heart rate and blood pressure control. While exercise is generally healthy, intense exertion can, in some genetically predisposed individuals, trigger neurally-mediated syncope if their autonomic system struggles to maintain adequate cerebral blood flow. It's a complex interplay of your body's regulatory processes and genetic makeup.
4. I have high blood pressure; does that raise my fainting risk?
There's a shared genetic background between syncope and conditions like hypertension and coronary artery disease. Your body's regulation of blood pressure is crucial in preventing syncope, so if you have high blood pressure, it indicates a potential vulnerability in your cardiovascular system. Managing your blood pressure well is important for reducing your overall cardiovascular risk, which can indirectly affect syncope risk.
5. Does my anxiety make me faint more often?
Genetic overlap has been noted between syncope and psychiatric phenotypes such as depression and attention deficit hyperactivity. While a direct, robust genetic link with anxiety specifically is still being explored and requires more definitive evidence, managing stress and anxiety is generally beneficial for your overall physiological well-being, which can influence your body's responses to triggers.
6. Could my fainting be a serious heart problem?
Yes, syncope can absolutely be the only presenting symptom of serious underlying genetic cardiac arrhythmias. Conditions like long QT and short QT syndromes, Brugada syndrome, and catecholaminergic polymorphic ventricular tachycardia are all genetic heart conditions that can manifest as fainting spells. A thorough cardiac assessment is crucial to rule out these potentially life-threatening causes.
7. Would a genetic test help explain my fainting spells?
Genetic testing is an emerging tool that could help understand your predisposition to syncope. Recent genome-wide association studies have identified specific genetic variants associated with syncope, such as a variant in PTPRN2 or at locus 2q32.1. While not always definitive for diagnosis, identifying these variants can offer insights into your unique genetic architecture and guide further clinical investigation, especially if a genetic cardiac condition is suspected.
8. Does what I eat affect my chances of fainting?
Cell-type specific analyses reveal that genetic variants associated with syncope are significantly enriched in regulatory elements of the adrenal and pancreas. This suggests the endocrine system plays a role in syncope pathogenesis. While direct dietary links aren't explicitly detailed, factors influencing these endocrine organs could potentially impact your susceptibility to fainting.
9. My grandma faints more now; is that normal for older people?
Yes, it's common for syncope incidence to increase with age, with the highest rates observed in women over 80 years old. As people age, their cardiovascular and autonomic nervous systems can become less efficient at regulating blood pressure and heart rate. This means that genetic predispositions might become more pronounced or interact with age-related physiological changes, making fainting more likely.
10. Why do some people faint from seeing blood, but I don't?
Vasovagal syncope, which can be triggered by emotional stress or specific sights like blood, is the most frequent type of syncope. Family aggregation studies and twin studies suggest a complex genetic inheritance pattern for vasovagal syncope. This means some individuals are genetically predisposed to have a stronger reflex response, involving their neural regulatory processes, to such triggers compared to others.
This FAQ was automatically generated based on current genetic research and may be updated as new information becomes available.
Disclaimer: This information is for educational purposes only and should not be used as a substitute for professional medical advice. Always consult with a healthcare provider for personalized medical guidance.
References
[1] Brignole, M., et al. "2018 ESC Guidelines for the diagnosis and management of syncope." Eur Heart J, vol. 39, 2018, pp. 1883–1948.
[2] Moya, A., et al. "Guidelines for the diagnosis and management of syncope (version 2009)." Eur Heart J, vol. 30, 2009, pp. 2631–2671.
[3] Ganzeboom, K. S., et al. "Lifetime cumulative incidence of syncope in the general population: a study of 549 Dutch subjects aged 35-60 years." J Cardiovasc Electrophysiol, vol. 17, 2006, pp. 1172–1176.
[4] Soteriades, E. S., et al. "Incidence and prognosis of syncope." N Engl J Med, vol. 347, 2002, pp. 878–885.
[5] Alshekhlee, A., et al. "Incidence and mortality rates of syncope in the United States." Am J Med, vol. 122, 2009, pp. 181–188.
[6] Aegisdottir HM, Thorolfsdottir RB, Sveinbjornsson G, et al. "Genetic variants associated with syncope implicate neural and autonomic processes." Eur Heart J, 2023 Mar 21;44(12):1070-1080.
[7] Mathias, C. J., et al. "Frequency of family history in vasovagal syncope." Lancet, vol. 352, 1998, pp. 33–34.
[8] Hadji-Turdeghal K, et al. "Genome-wide association study identifies locus at chromosome 2q32.1 associated with syncope and collapse." Cardiovasc Res, 2019 May 1;116(1):138–148.
[9] Hedley, P. L., et al. "The genetic basis of long QT and short QT syndromes: a mutation update." Hum Mutat, vol. 30, 2009, pp. 1486–1511.
[10] Gussak, I., et al. "Brugada syndrome: a decade of progress in understanding the pathogenesis and clinical management." J Electrocardiol, vol. 38, 2005, pp. 101-105.
[11] Winkel, B. G., et al. "Symptoms preceding sudden death in the young: a Danish forensic study." Europace, vol. 14, 2012, pp. 1493–1499.
[12] Kapoor, W. N. "Syncope." N Engl J Med, vol. 343, 2000, pp. 1856–1862.
[13] Ruwald, M. H., et al. "Accuracy of the ICD-10 discharge diagnosis for syncope." Europace, vol. 15, 2013, pp. 595–600.
[14] Reilly, John G., et al. "QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients." Lancet, vol. 355, 2000, pp. 1048–1052.
[15] Marquez, M. F., et al. "The Arg389Gly beta1-adrenergic receptor gene polymorphism and susceptibility to faint during head-up tilt test." Europace, vol. 9, 2007, pp. 585–588.
[16] Lelonek, M., et al. "Mutation T/C, Ile 131 of the gene encoding the alfa subunit of the human Gs protein and predisposition to vasovagal syncope." Circ J, vol. 72, 2008, pp. 558–562.
[17] Saadjian, A. Y., et al. "Head-up tilt induced syncope and adenosine A2A receptor gene polymorphism." Eur Heart J, vol. 30, 2009, pp. 1510–1515.
[18] Sorrentino, S., et al. "Endothelin system polymorphisms in tilt test-induced vasovagal syncope." Clin Auton Res, 2009.